Month: November 2015

November 30, 2015, by Shakun Malik, M.D. A cytotoxic T cell (left) engaging a cancer cell (round cell, center). Credit: A. Ritter, J. Lippincott-Schwartz / NICHD As recently as a decade ago, a patient diagnosed with advanced lung cancer had a straightforward choice of treatments: chemotherapy or palliative measures. Many oncologists advised their patients against
0 Comments
November 25, 2015, by NCI Staff T-VEC, an oncolytic virus, works by infecting and killing tumor cells, like these dividing melanoma cells, and stimulating an immune response against cancer cells throughout the body. Credit: Wellcome Images, CC BY-NC-ND 4.0 On October 27, the U.S. Food and Drug Administration (FDA) approved the first oncolytic virus therapy, talimogene
0 Comments
November 18, 2015, by NCI Staff Pembrolizumab targets a protein on immune cells called PD-1, one of a family of so-called checkpoint proteins that can restrain the immune response. Credit: National Cancer Institute / Terese Winslow On October 2, the Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab (Keytruda®) to treat patients with
0 Comments
November 12, 2015, by NCI Staff New findings in mice suggest that antioxidant supplements may promote tumor metastasis. Credit: iStock Evidence from two new studies in mice shows that antioxidants—dietary supplements commonly used in the belief that they may help prevent disease—may actually promote tumor growth and metastasis.  The new findings, authors from both studies
0 Comments
November 5, 2015, by L.M. Bennett, W. McCaskill-Stevens, S. Springfield Join the Conversation Share your thoughts below in the comments. And be part of a Twitter chat on cancer health disparities research being held on November 18 at 3:00 p.m. ET. Visit our social media events page for more information. The following is the fourth
0 Comments